TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01515930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Computer-Delivered Motivational Intervention
Description: Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding monitoring diabetes care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent & Child Computer-Delivered Motivational Intervention
Description: Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding diabetes care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Delivered Information
Description: Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
Study: NCT01938404

Intervention type: BIOLOGICAL
Intervention: Octaplas
Description: Octoplas infusion solution for IV administration

Intervention type: DRUG
Intervention: Standard Plasma
Description: Plasma given as replacement fluid
Study: NCT02824718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: human recombinant parathormone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazide
Description: Diuretic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium sparing diuretic
Description: Diuretic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol
Description: Belongs to the class of vitamin D and analogues
Study: NCT03137927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine GamLPV
Description: live intranasal vaccine for whooping cough prevention

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine GamLPV
Description: live intranasal vaccine for whooping cough prevention

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine GamLPV
Description: live intranasal vaccine for whooping cough prevention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02476409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolvaptan
Description: Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
Study: NCT04131543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 20 MG
Description: Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 MG
Description: Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 MG
Description: Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
Study: NCT02253030

Intervention type: DEVICE
Intervention: Optical Coherence Tomography

Intervention type: DEVICE
Intervention: Optical Coherence Tomography

Intervention type: DEVICE
Intervention: Optical Coherence Tomography

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Study: NCT00714493

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Infliximab
Description: 3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
Study: NCT04650152

Intervention type: DRUG
Intervention: Tricor (fenofibrate), 145 mg, film-coated tablet
Description: Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
Study: NCT04046796

Intervention type: GENETIC
Intervention: NGS Diagnostic
Description: Blood take for genetic diagnostic.

Intervention type: GENETIC
Intervention: NGS Diagnostic
Description: Blood take for genetic diagnostic.
Study: NCT02058212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ascorbate 1000mg, vitamin E 400, zinc and selenium
Description: anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ascorbate 1000mg, vitamin E 400, zinc and selenium
Description: anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
Study: NCT00368901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
Study: NCT05367479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Peri-operative, intravenous antibiotic for surgical site infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Peri-operative, intravenous antibiotic for surgical site infection
Study: NCT00793780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone 25mg
Description: Naltrexone 25mg caplets taken orally once a day for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caplet (inactive substance) taken orally once a day for 8 weeks
Study: NCT05288036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Rehabilitation group
Description: The PNF technique was performed in the supine position with the hip joints of the patients in 30° flexion and the lower extremities in semi-flexion. The application was performed in 2 different diagonal and 4 different patterns (flexion-abduction-external rotation/extension-abduction-internal rotation, and flexion-adduction-external rotation/extension-abduction-internal rotation) of the upper extremity. When starting the exercise, the muscles were first brought to their longest position and the patient was asked to move in the direction of the pattern with resistance (concentric contraction) and to maintain this position for 6 seconds at the end of the pattern (isometric contraction). Then, while the therapist was taking the patient's arm to the starting position, the patient was asked to prevent movement (eccentric contraction). All of these moves counted as one repetition. 3 sets of 8-12 repetitions were performed for each pattern.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise Group
Description: Strengthening exercises targeting the upper extremity main muscles were applied to the PRE group with progressive resistance. Dumbbells and sandbags were used as resistance equipment. resistance intensity; 50-80% of a repetition maximum (RM) was determined according to the patient's tolerance. The exercises were applied as 8-12 repetitions and 3 sets. A rest period of 60-90 seconds was allowed between each set. After the 4th week of the training, 1 RM was measured again and the resistance density was updated. The 8 strengthening exercises to be applied were created by taking examples from the literature and in accordance with the Guidelines for implementing exercise programs exercise programs for cancer patients. These exercises are: dumbbell fly, triceps extension, biceps curl up, one-arm bent over row, dumbbell sides rise, lifting the arm forward, wrist curl and side lying shoulder internal -external rotation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The patients in the control group were instructed to continue their usual daily lives (not changing their physical activity levels, diet, drug use, etc.) until the date of re-evaluation after the initial evaluation. Information was given about the upper extremity normal range of motion exercises that they could apply at home, and a brochure was given.
Study: NCT03894748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Study: NCT00759239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% / Timolol maleate 0.5%
Description: Solution, morning dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% / Timolol maleate 0.5%
Description: Solution, evening dosing
Study: NCT03040323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason 60.7Mg Powder for Injection
Description: Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos injected prior to ultrasound-guided biopsy
Study: NCT03011190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional regulation
Description: Educate people with difficulty in regulating their emotions and help them acquire skills to do so

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotional regulation
Description: Educate people with difficulty in regulating their emotions and help them acquire skills to do so
Study: NCT02379195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 are administered i.v on day -5 to -1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL infusion
Description: The maximum number of expanded TILs are infused over 30-45 min on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
Study: NCT04301661

Intervention type: OTHER
Intervention: Blood collection
Description: Blood will be collected from participants at defined time points during the study to measure drug levels and assess platelet activity.

Intervention type: OTHER
Intervention: Blood collection
Description: Blood will be collected from participants at defined time points during the study to measure drug levels and assess platelet activity.
Study: NCT02476409

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for tolvaptan
Study: NCT01007396

Intervention type: OTHER
Group type: OTHER
Intervention: 1-step tuberculin skin test (TST) and blood sampling
Description: In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
Study: NCT01408524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: 2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: 2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Study: NCT04301661

Intervention type: OTHER
Intervention: Blood collection
Description: Blood will be collected from participants at defined time points during the study to measure drug levels and assess platelet activity.

Intervention type: DRUG
Intervention: Abacavir/lamivudine
Description: Participants who are already taking abacavir/lamivudine as part of standard HIV care will continue taking their therapy.

Intervention type: DRUG
Intervention: Tenofovir alafenamide/emtricitabine
Description: Participants who are already taking tenofovir alafenamide/emtricitabine as part of standard HIV care will continue taking their therapy.
Study: NCT05693870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed space maintainer
Description: Appliance bonded with composite resin or/banded and cemented with glass ionomer cement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed space maintainer
Description: Appliance bonded with composite resin or/banded and cemented with glass ionomer cement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed space maintainer
Description: Appliance bonded with composite resin or/banded and cemented with glass ionomer cement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed space maintainer
Description: Appliance bonded with composite resin or/banded and cemented with glass ionomer cement
Study: NCT04301661

Intervention type: DRUG
Intervention: Switch
Description: Participants who are planning to switch from abacavir/lamivudine as part of standard HIV care will change therapy to per the discretion of their HIV provider.
Study: NCT01628068

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial appendage occlusion
Description: Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
Study: NCT02051504

Intervention type: PROCEDURE
Intervention: Accelerometry over one week
Description: The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level

Intervention type: PROCEDURE
Intervention: Accelerometry over one week
Description: The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level

Intervention type: PROCEDURE
Intervention: Accelerometry over one week
Description: The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level

Intervention type: PROCEDURE
Intervention: Accelerometry over one week
Description: The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level

Intervention type: OTHER
Intervention: Questionnaires
Description: Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires

Intervention type: OTHER
Intervention: Questionnaires
Description: Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires

Intervention type: OTHER
Intervention: Questionnaires
Description: Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires

Intervention type: OTHER
Intervention: Questionnaires
Description: Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
Study: NCT01036893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: prucalopride 2 mg oral dosing o.d. for 6 days
Study: NCT02582983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
Study: NCT01528475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-hospital cooling
Description: Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
Study: NCT02059395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mastery based learning
Description: Participants are allowed to follow the course content at their own speed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time based learning
Description: Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
Study: NCT02725905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modal Education (MME)
Description: The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Education (TE)
Description: Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
Study: NCT02390492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 treatment
Description: 200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 treatment
Description: 200-mg/100-mcCi oral \[14C\]-ipatasertib on Day 15 of study
Study: NCT01891981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox
Description: Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I.
Study: NCT02308293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: 3x30 seconds 'all out' sprints

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lay down comfortably
Description: rest
Study: NCT00873197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only.
Study: NCT04971343

Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_blood donor
Description: Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Roche - Cobas - Elecsys® HIV Duo .~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested).

Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_Hospitalized patient
Description: All samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay for hospitalized patient.~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested).

Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_known HIV-1 antibody positives
Description: Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay .~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.~In case of discrepant results or concordant negative results between Access and Reference HIV Ag/Ab combo assay among known HIV-1 antibody positive patients, the IB/WB test will be repeated by the site to confirm sample status. If this IB/WB result is negative or indeterminate, the sample will be excluded from the statistical analysis
Study: NCT04223063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: As per the intervention arm